Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): A randomised, open-label, multicentre, phase 2 trial

1. Cortés, J.
2. Dieras, V.
3. Ro, J.
4. Barriere, J.
5. Bachelot, T.
6. Hurvitz, S.
7. Le Rhun, E.
8. Espié, M.
9. Kim, S.-B.
10. Schneeweiss, A.
11. Sohn, J.H.
12. Nabholtz, J.-M.
13. Kellokumpu-Lehtinen, P.-L.
14. Taguchi, J.
15. Piacentini, F.
16. Ciruelos, E.
17. Bono, P.
18. Ould-Kaci, M.
19. Roux, F.
20. Joensuu, H.